American Academy of Allergy, Asthma and Immunology

Recent papers from American Academy of Allergy, Asthma and Immunology

1. Accuracy of commercial pollen forecasts in the United States2026
2. Emerging agents and regimens for myeloproliferative neoplasms: updates from ASH 2025 Annual MeetingExperimental Hematology and Oncology · 2026
3. ARIA‐EAACI 2025: Person‐Centred, Digitally Enabled and Artificial Intelligence‐Assisted Change Management in Airway DiseasesClinical and Translational Allergy · 2026
4. Pollen Season Timing and Concentrations in the United States: Developing a Standardized Pollen Dataset Using Data from the National Allergy Bureau (NAB) (2003–2024)Atmosphere · 2026
5. Availability and Costs of Allergic Rhinitis Treatments Across the World: A Survey of ARIA ExpertsAllergy · 2026
6. Evaluating pozelimab in the treatment of CHAPLE diseaseImmunotherapy · 2026
7. Allergic Rhinitis and Its Impact on Asthma ( ARIA )‐ EAACI Guidelines—2024–2025 Revision: Part I—Guidelines on Intranasal TreatmentsTyöväentutkimus Vuosikirja · 2025
8. Sustained Effectiveness, Tolerability, and Safety of Long-Term Prophylaxis with Lanadelumab in Hereditary Angioedema: The Prospective, Phase 4, Noninterventional EMPOWER Real-World StudyAdvances in Therapy · 2025
9. Blended problem based learning in postgraduate education: The Eastern Allergy Conference and the PBL Institute experienceAllergy and Asthma Proceedings · 2025
10. Identificación y sensibilización a hongos ambientales en Lima, PerúDeleted Journal · 2024
11. Ige Reactivity of a Recombinant Multi-Epitope Protein Designed From Allergens of Interest in the Tropics - Preliminary Findings.Deleted Journal · 2024
12. Systematic symptom management in the IMPACT Consortium: rationale and design for 3 effectiveness-implementation trialsJNCI Cancer Spectrum · 2023
13. Allergic diseases and immunodeficiencies in children, lessons learnt from COVID ‐19 pandemic by 2022: A statement from the EAACI ‐section on pediatricsPediatric Allergy and Immunology · 2022
14. Novel agents and regimens for hematological malignancies: recent updates from 2020 ASH annual meetingJournal of Hematology & Oncology · 2021
15. Therapy of allergic rhinitis in routine care: evidence-based benefit assessment of freely combined use of various active ingredientsAllergo Journal International · 2020
16. Update on penicillin allergy delabelingCurrent Opinion in Pediatrics · 2020
17. Use of biologicals in allergic and type-2 inflammatory diseases during the current COVID-19 pandemicAllergologie select · 2020
18. Critical view of anaphylaxis epidemiology: open questions and new perspectivesAllergy Asthma and Clinical Immunology · 2018
19. Lack of asthma and rhinitis control in general practitioner-managed patients prescribed fixed-dose combination therapy in AustraliaJournal of Asthma · 2017
20. Applying prevention concepts to anaphylaxis: A call for worldwide availability of adrenaline auto‐injectorsClinical & Experimental Allergy · 2017